Advertisement
Advertisement
U.S. markets close in 5 hours 51 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.1000-0.0100 (-0.32%)
As of 09:44AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.1100
Open3.0800
Bid2.9400 x 1100
Ask3.1300 x 800
Day's Range3.0250 - 3.1100
52 Week Range2.7600 - 15.7900
Volume549
Avg. Volume496,355
Market Cap115.37M
Beta (5Y Monthly)N/A
PE Ratio (TTM)8.16
EPS (TTM)0.3800
Earnings DateAug 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VACC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vaccitech plc
    Daily – Vickers Top Insider Picks for 09/07/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    23 days agoArgus Research
View more
  • GlobeNewswire

    Vaccitech Promotes Gemma Brown as Chief Financial Officer

    OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma Brown as Chief Financial Officer (CFO). Gemma Brown succeeds Georgy Egorov. “Gemma has been highly engaged with all financial activities at Vaccitech including working with our auditors, corporate budgeting, SEC financial filings and other activi

  • GlobeNewswire

    Vaccitech to Present at Upcoming September Investors Conferences

    OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September. Event:Morgan Stanley 20th Annual Healthcare Conference 2022, New York CityDate:Monday, Sept

  • Zacks

    Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why

    Vaccitech PLC Sponsored ADR (VACC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Advertisement
Advertisement